To provide an overview of aerosol drug therapy, including physical considerations and aerosol drug delivery systems, and to review clinical experience with inhaled antibiotics in cystic fibrosis (CF) when used as adjunctive therapy to intravenous therapy for acute pulmonary exacerbations and chronic, suppressive therapy.
DATA SOURCES:
A MEDLINE search (1966-1995) of English-language literature describing the use of inhaled antibiotics for the management of CF.
STUDY SELECTION AND DATA EXTRACTION:
All articles were considered for possible inclusion in the review. Pertinent information as judged by the authors was selected for discussion.
DATA SYNTHESIS:
The use of inhaled antibiotics as adjunctive therapy to systemic therapy for acute exacerbations did not improve pulmonary function tests, increase hospital discharge rate, or permanently eradicate sputum Pseudomonas. Clinical trials of inhaled antibiotics as suppressive therapy yielded variable results. Individually, four trials documented a significant improvement in pulmonary function, three trials documented a slower decline in pulmonary function, and four trials reported a reduced frequency of hospitalizations. However, the trials were unable to collectively document a prolonged beneficial effect of inhaled antibiotics on pulmonary function, sputum bacterial density, and frequency of hospitalizations.
CONCLUSIONS:
Clinical trials conducted thus far suggest no role for inhaled antibiotics in the treatment of acute pulmonary exacerbations in patients with CF. Aerosolized antibiotics used as suppressive therapy may be useful in certain patients, but their use should be limited to select patients based on individual response to therapy. Additional long-term, well-controlled trials of inhaled antibiotics as suppressive therapy are needed before routine use can be recommended.
Get full access to this article
View all access options for this article.
References
1.
ZachMS. Pathogenesis and management of lung disease in cystic fibrosis. J R Soc Med1991; 84 (suppl 18): 10–7.
2.
RiordanJRRommensJMKeremBTAlonNRozmaheiR. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science1989; 245: 1066–73.
3.
KeremBTRommensJMBuchananJAMarkiewicsDCoxTK. Identification of the cystic fibrosis gene: genetic analysis. Science1989; 245: 1073–80.
4.
RommensJMIannuzziMCKeremBTDrummMLMelmerG. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science1989; 245: 1059–65.
5.
TsuiL. The spectrum of cystic fibrosis mutations. Trends Genet1992; 8: 392–8.
6.
ZachMS. Lung disease in cystic fibrosis — an updated concept. Pediatr Pulmonol1990; 8: 188–202.
CoreyMAllisonLProberCLevisonH. Sputum bacteriology in patients with cystic fibrosis in a Toronto hospital. J Infect Dis1984; 149: 283.
9.
MacLuskyIBLevisonHGoldRMcLaughlinFJ. Inhaled antibiotics in cystic fibrosis: is there a therapeutic effect?J Pediatr1986; 108: 861–5.
10.
LevyJ. Antibiotic therapy in cystic fibrosis: evaluation of efficacy. Chest1988; 94 (2 suppl150S–3S.
11.
HoibyN. Antibiotic therapy for chronic infection of Pseudomonas in the lung. Annu Rev Med1993; 44: 1–10.
12.
Loening-BauckeVAMischlerEMyersMG. A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis. J Pediatr1979; 95: 630–7.
13.
HoibyNPedersenSSJensenTValeriusNHKochC. Fluoroquinolones in the treatment of cystic fibrosis. Drugs1993; 45 (suppl 3): 98–101.
14.
MendelmanPMSmithALLevyJWeberARamseyBDavisRL. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis. Am Rev Respir Dis1985; 132: 761–5.
15.
WallaceCSHallMKuhnRJ. Pharmacologic management of cystic fibrosis. Clin Pharm1993; 12: 657–74.
GerrityTRLeePSHassFJMarinelliAWernerPLourencoRV. Calculated deposition of inhaled particles in the airway generations of normal subjects. J Appl Physiol1979; 47: 867–73.
18.
SwiftDL. Generation and respiratory deposition of therapeutic aerosols. Am Rev Respir Dis1980; 122: 71–7.
19.
PaviaDThomsonMLClarkSWShannonHS. Effect of lung function and mode of inhalation on penetration of aerosol into the human lung. Thorax1977; 32: 194–7.
GoldbergISLourencoRV. Deposition of aerosols in pulmonary disease. Arch Intern Med1973; 131: 88–91.
22.
MukhapadhyaySStaddonGEEastmanCPalmerMDaviesERCarswellF. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir Med1994; 88: 203–11.
23.
IlowiteJSGorvoyJDSmaldoneGC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis1987; 136: 1445–9.
24.
AldersonPOSecker-WalkerRHStomingerDB. Pulmonary deposition of aerosols in children with cystic fibrosis. J Pediatr1974; 84: 479–84.
25.
HardyJGNewmanSPKnochM. Lung deposition from four nebulizers. Respir Med1993; 87: 461–5.
26.
WeberASmithAWilliams-WarrenJRamseyBCovertDS. Nebulizer delivery of tobramycin to the lower respiratory tract. Pediatr Pulmonol1994; 17: 331–9.
27.
StoutSADerendorfH. Local treatment of respiratory infections with antibiotics. Drug Intell Clin Pharm1987; 21: 322–9.
28.
CooneyGFLumBLTomaselliMFielSB. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharmacol1994; 34: 255–9.
29.
NewmanSPPellowPGDClarkeSW. Choice of nebulizers and compressors for delivery of carbenicillin aerosol. Eur J Respir Dis1986; 69: 160–8.
30.
NewmanSPPellowPGDClayMMClarkeSW. Evaluation of jet nebulizers for use with gentamicin solution. Thorax1985; 40: 671–6.
31.
NewmanSPWoodmanGClarkeSW. Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern. Thorax1988; 43: 318–22.
32.
HungJCCHambletonGSuperM. Evaluation of two commercial jet nebulizers and three compressors for the nebulization of antibiotics. Arch Dis Child1994; 71: 335–8.
33.
Di Sant AgnesePAAndersonDA. Celiac syndrome. Am J Dis Child1946; 72: 17–61.
34.
BoxerbaumBPittmanSDoershukCFSternRCMatthewsLW. Use of gentamicin in children with cystic fibrosis. J Infect Dis1971; 124 (suppl): S293–5.
35.
HoffGESchiotzPOPaulsenJ. Tobramycin treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Scand J Infect Dis1974; 6: 333–7.
36.
HuangNNHillerEJMacriCMCapitanioMCundyKR. Carbenicillin in patients with cystic fibrosis: clinical pharmacology and therapeutic evaluation. J Pediatr1971; 78: 338–45.
SmithAL. Antibiotic therapy in cystic fibrosis: evaluation of clinical trials. J Pediatr1986; 108: 866–70.
39.
SmithALRamseyB. Aerosol administration of antibiotics. Pediatr Pulmonol1995; 11 (suppl): 68–9.
40.
FielSB. Aerosol delivery of antibiotics to the lower airways of patients with cystic fibrosis. Chest1995; 107 (2; suppl): 61S–4S.
41.
StephensDGareyNIslesALevisonHGoldR. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr Infect Dis J1983; 3: 209–11.
42.
SchaadUBWedgewoodKruckoJSuterSKraemerR. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr1987; 111: 599–605.
43.
HodsonMEPenkethARLBattenJC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet1981; 2: 1137–9.
44.
KunPLandauLIPhelanPD. Nebulized gentamicin in children and adolescents with cystic fibrosis. Aust Paediatr J1984; 20: 43–5.
45.
CarswellFWardCCookDASpellerDCE. A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis. Br J Dis Chest1987; 81: 356–60.
46.
MacLuskyIBGoldRCoreyMLevisonH. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol1989; 7: 42–8.
SmithALRamseyBWHedgesDLHackBWilliams-WarrenJWeberA. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol1989; 7: 265–71.
49.
RamseyBWDorkinHLEisenbergJDGibsonRLHarwoodIRKravitzRM. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med1993; 328: 1740–6.
50.
WallMATerryABEisenbergJMcNamaraM. Inhaled antibiotics in cystic fibrosis (letter). Lancet1983; 1: 1325.
51.
WittenbergDF. Maintenance of Pseudomonas antibiotic sensitivity in patients with cystic fibrosis treated with inhaled antibiotics (letter). S Afr Med J1987; 77: 335–6.
52.
LittlewoodJMMillerMGGhoneimATRamsdenCH. Nebulized colomycin for early Pseudomonas colonization in cystic fibrosis (letter). Lancet1985; 1: 865.
53.
JensenTPedersenSSGarneSHeilmannCHoibyNKochC. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother1987; 19: 831–8.
54.
ValeriusNHKochCHoibyN. Prevention of Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment. Lancet1991; 338: 725–6.
55.
NolanGMcIvorPLevisonHFlemingPCCoreyMGoldR. Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin. J Pediatr1982; 101: 626–30.
56.
SteadRJHodsonMEBattenJC. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest1987; 81: 272–9.
57.
HolzerFJOlinskyAPhelanPD. Variability of airways hyperreactivity and allergy in cystic fibrosis. Arch Dis Child1981; 56: 455–9.
58.
LevyJSmithALKennyMA. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J Infect Dis1983; 148: 1069–76.
59.
ChrispinARNormanAP. The systematic evaluation of the chest radiograph in cystic fibrosis. Pediatr Radiol1974; 2: 101–6.
60.
BossoJALiptakCASeilheimerDKHarrisonGM. Toxicity of colistin in cystic fibrosis patients. DICP Ann Pharmacother1991; 25: 1168–70.
61.
BauldoffGSNunleyDRManzettiJDWilliamsPIaconoATDauberJH. Use of aerosolized colistin in patients with cystic fibrosis awaiting lung transplantation (abstract). Pediatr Pulmonol1995; 12 (suppl): 257–8.
